We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Exelixis Drops Cabozantinib in Prostate Cancer Trial
Exelixis Drops Cabozantinib in Prostate Cancer Trial
San Francisco-based drugmaker Exelixis is halting research into the use of its thyroid cancer therapy Cometriq for treating prostate cancer after the drug failed a Phase III trial for that indication.